Segvende Search

may be administered in an anti-bronchoconstriction and/or anti-inflammation effective amt. to alleviate the bronchoconstriction and inflammation afflicting a subject. Preferred agents contain anti-sense oligonucleotide targeting the adenosine A1, A2a, A2b and/or A3 receptors and bradykinin B2 receptor. The method is useful for treating patients afflicted with asthma and other respiratory problems. Pharmaceutical formulations are also disclosed.

=> d his

(FILE 'HOME' ENTERED AT 18:31:22 ON 02 DEC 1999) FILE 'REGISTRY' ENTERED AT 18:33:48 ON 02 DEC 1999 249 S GATGGAGGGCGGCATGGCGGG/SQSN FILE 'CAPLUS' ENTERED AT 18:36:24 ON 02 DEC 1999 5 S L1 AND ADENOSINE FILE 'REGISTRY' ENTERED AT 18:38:31 ON 02 DEC 1999 4 S GTTGTTGGGCATCTTGCC/SQSN FILE 'CAPLUS' ENTERED AT 18:39:34 ON 02 DEC 1999 3 S L3 AND ANTISENSE S GTGGGCCTAGCTCTCGCC/SQSN FILE 'REGISTRY' ENTERED AT 18:40:52 ON 02 DEC 1999 1 S GTGGGCCTAGCTCTCGCC/SOSN FILE 'CAPLUS' ENTERED AT 18:41:06 ON 02 DEC 1999 3 S L5 S GGCGGCCTGGAAAGCTGAGATGGAGGGCGGCATGGCGGGCACAGGCTGGGC/SQSN FILE 'REGISTRY' ENTERED AT 18:42:55 ON 02 DEC 1999 2 S GGCGGCCTGGAAAGCTGAGATGGAGGGCGGCATGGCGGCACAGGCTGGGC/SQSN FILE 'CAPLUS' ENTERED AT 18:43:09 ON 02 DEC 1999 L8 2 S L7 => log y COST IN U.S. DOLLARS SINCE FILE TOTAL **ENTRY** SESSION FULL ESTIMATED COST 4.85 131.95 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -1.07-6.97

STN INTERNATIONAL LOGOFF AT 18:43:47 ON 02 DEC 1999